Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort

摘要: Introduction Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib, dabrafenib, sorafenib as inhibitors are currently tested in clinical trials, but access for patients is limited. The aim this study was to document the course treated outside trials. Methods We conducted a retrospective multicenter cohort Europe with advanced BRAF-mutant cancer known inhibitors. Data were anonymized centrally assessed age, gender, smoking, histology, stage, local molecular diagnostic results, systemic therapies, survival. Best response locally by RECIST1.1. Results documented 35 17 centers vemurafenib, or sorafenib. Median age 63 years (range 42–85); gender balanced; 14 (40%) never smokers; all (100%) had adenocarcinoma; 29 (83%) V600E; 6 (17%) mutations; one them concomitant KRAS mutation. Thirty (86%) chemotherapy first line. Overall survival first-line therapy 25.3 months 11.8 non-V600E. Thirty-one received inhibitor, four second inhibitor. rate 53%, disease control 85%. progression-free 5.0 months, overall 10.8 months. Conclusions These results confirm activity targeted adenocarcinoma. Further trials warranted combination therapies drug resistance mechanisms.